The Cause-Effect Dilemma of Hematologic Changes in COVID-19: One Year after the Start of the Pandemic

COVID-19 is a systemic infection that leads to multisystem affection, including hematological changes. On the other hand, the patients who have certain hematological diseases are more susceptible to COVID-19 infection. The aim of this review is to examine the wide spectrum of hematological changes that are reported to occur due to COVID-19 infection. Most of the studies over the past year mainly show that most of these changes are mainly non-specific, but are of prognostic value. On the other hand, the susceptibility of hematological patients to COVID-19 infection and complications remains questionable. Patients with certain hematological diseases (including malignancy) and those who are treated by aggressive immunosuppressive therapy have shown higher rates of COVID-19 infection and complications. On the other hand, for most of the patients suffering from other chronic hematological conditions, no evidence has shown a greater risk of infection, compared to the general population.

Automated summary

COVID-19 infection can cause hematological changes, most of which are non-specific but have prognostic value. Patients with certain hematological diseases and those receiving aggressive immunosuppressive therapy are more susceptible to COVID-19, while most patients with other chronic hematological conditions do not have a significantly higher risk of infection compared to the general population.